However, in patients who harbored a germline pathogenic BRCA1/2 mutation, only 70% of these germline mutations were identified with tumor testing, while 30% of germline mutations were missed, due to either technical or interpretative errors [19]. Here, BRCA1 is linked to neoplasm.